Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study),” which he presented in New York City, New York.
At ASRS in New York, Matthew Starr, MD, presented, “Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases.”
At ASRS in New York City, Charles Wykoff, MD, presented a talk entitled, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” The trial demonstrated large improvements for patients with diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), with notable improvements according to the Diabetic Retinopathy Severity Scale (DRSS).
The future risk of the development of new-onset vision-threatening diabetic retinopathy, diabetic macular edema, and proliferative diabetic retinopathy can be predicted using the patient’s retinopathy status and hemoglobin A1c value.
Metformin, a frequently prescribed drug to treat diabetes, could be a novel therapy for AMD.
At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.
Investigators from Thailand took a close look at retinal fluid fluctuations in Thai patients with wet age-related macular degeneration (AMD) and devised a better way to measure the fluctuations in the central subfield thickness (CST).
Christopher Henry, MD, presented a talk entitled, “Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis,” at ASRS 2022 in New York City, New York.
Rhegmatogenous detachments increased with age; myopia, trauma, and history of retinopathy were common underlying risk factors for development of rhegmatogenous retinal detachments.
At ASRS in New York City, New York, David Eichenbaum, MD, presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”
Treatment with faricimab in patients with neovascular AMD achieved improvements in the visual acuity, central subfield thickness, and pigment epithelial detachments.
At ASRS 2022, Raj K. Maturi, MD, presented a talk entitled, “UBX1325, A Novel Senolytic Therapy for Treatment- Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study.”
At ASRS in New York City, New York, Justis Ehlers, MD, presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.
Albert J. Augustin, MD, presented a talk entitled, “First Results of the Miniature Telescope in Dry AMD” in Fort Lauderdale, Florida. The Galilean telescope device offers visual improvements for patients with late-stage AMD.
Results from our recent poll regarding ASRS 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in New York, New York.
The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York.
Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
A poll for retina specialists regarding their attendance at the 2022 American Society of Retina Specialists 40th Annual Scientific Meeting in New York City, New York. This poll is now closed.
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.
Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.
The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.
While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
Yasha S. Modi, MD, discusses his best tips and tricks for finding and diagnosing infectious uveitis.
Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.
